University Clinic of Medicine, Cantonal Hospital Baselland, Liestal, Switzerland.
Boehringer Ingelheim GmbH, Basel, Switzerland.
Curr Med Res Opin. 2021 Nov;37(11):2019-2033. doi: 10.1080/03007995.2021.1969354. Epub 2021 Sep 7.
The aims of the survey were to assess first experiences of Swiss COPD patients switching from the disposable to the new reusable Respimat inhaler, and to evaluate physicians´ and patients´ views of the new training material.
Patients with a confirmed diagnosis of COPD using a disposable Respimat inhaler for at least three months were included. Patients´ demographics, COPD stage, current treatment, and comorbidities relevant for the handling of the device were assessed. Further, patients were trained on the reusable Respimat by placebo inhaler, patient brochure, video cards/demo films and SMS reminder service. After at least one cartridge change, patients gave comprehensive feedback on their satisfaction with the reusable Respimat and physicians evaluated the need for re-training.
235 patients participated in the survey. Of these, 37% suffered from comorbidities restricting the handling of the Respimat. 216 (92%) patients had a better overall satisfaction with the reusable than with the disposable Respimat. Dose counter (86%), monthly preparation (81%) and daily handling (77%) were also assessed as better by most of the patients. In 80% of cases, the user ability was stated as better than for the disposable Respimat. Less than 15% of the patients required further training. Placebo inhaler was the mostly preferred training material by both, physicians (in 86% of the patients) and patients (75%). In patients with comorbidities affecting inhaler handling, overall satisfaction was also better in 86% of the patients.
The majority of patients were satisfied with the new reusable Respimat device and proper handling could be attained using the provided training material, even in patients with restricting comorbidities.
本调查旨在评估瑞士 COPD 患者从一次性到新可重复使用的 Respimat 吸入器转换的初步体验，并评估医生和患者对新培训材料的看法。
纳入使用一次性 Respimat 吸入器至少三个月且确诊为 COPD 的患者。评估患者的人口统计学、COPD 分期、当前治疗方案和与设备处理相关的合并症。进一步，患者通过安慰剂吸入器、患者手册、视频卡/演示电影和短信提醒服务接受可重复使用的 Respimat 培训。在至少更换一个药筒后，患者对可重复使用的 Respimat 的满意度进行了全面反馈，医生评估了重新培训的需求。
共有 235 名患者参与了调查。其中，37%的患者患有合并症，限制了对 Respimat 的处理。216 名（92%）患者对可重复使用的 Respimat 的总体满意度高于一次性 Respimat。大多数患者还认为剂量计数器（86%）、每月准备（81%）和日常处理（77%）更好。在 80%的情况下，患者表示可重复使用的 Respimat 的使用能力比一次性 Respimat 更好。不到 15%的患者需要进一步培训。对于医生（在 86%的患者中）和患者（75%）来说，安慰剂吸入器都是最受欢迎的培训材料。在处理吸入器受到合并症影响的患者中，86%的患者总体满意度也更高。
大多数患者对新的可重复使用的 Respimat 设备感到满意，并且即使在有合并症限制的患者中，也可以通过提供的培训材料正确处理。
